Search publications
Title: Health services costs for cancer care in Australia: Estimates from the 45 and Up Study
Authors: Goldsbury DE; Yap S; Weber MF; Veerman L; Rankin N; Banks E; Canfell K; O'Connell DL
Categories: Cancer Type - All Cancers combined
Year: 2018
Journal Title: PLOS One
Volume: 13
Issue: 7
Page number start: e0201552
Abstract: Background Cancer care represents a substantial and rapidly rising healthcare cost in Australia. Our aim was to provide accurate population-based estimates of the health services cost of cancer care using large-scale linked patient-level data. Methods We analysed data for incident cancers diagnosed 2006–2010 and followed to 2014 among 266,793 eligible participants in the 45 and Up Study. Health system costs included Medicare and pharmaceutical claims, inpatient hospital episodes and emergency department presentations. Costs for cancer cases and matched cancer-free controls were compared, to estimate monthly/annual excess costs of cancer care by cancer type, before and after diagnosis and by phase of care (initial, continuing, terminal). Total costs incurred in 2013 were also estimated for all people diagnosed in Australia 2009–2013. Results 7624 participants diagnosed with cancer were matched with up to three controls. The mean excess cost of care per case was AUD$1,622 for the year before diagnosis, $33,944 for the first year post-diagnosis and $8,796 for the second year post-diagnosis, with considerable variation by cancer type. Mean annual cost after the initial treatment phase was $4,474/case and the mean cost for the last year of life was $49,733/case. In 2013 the cost for cancers among people in Australia diagnosed during 2009–2013 was ~$6.3billion (0.4% of Gross Domestic Product; $272 per capita), with the largest costs for colorectal cancer ($1.1billion), breast cancer ($0.8billion), lung cancer ($0.6billion) and prostate cancer ($0.5billion). Conclusions The cost of cancer care is substantial and varies by cancer type and time since diagnosis. These findings emphasise the economic importance of effective primary and secondary cancer prevention strategies.
Division: Cancer Research Division
Funding Body: EB and KC receive salary support from the National Health and Medical Research Council of Australia (PRF #1136128 and CDF #1082989 respectively). KC is an investigator on an unrelated investigator-initiated trial of cytology and primary HPV screening in Australia (Compass), which is conducted and funded by the Victorian Cytology Service (VCS), a government-funded health promotion charity.
DOI: doi.org/10.1371/journal. pone.0201552
URI: http://researchpubs.cancercouncil.com.au/cancercounciljspui/handle/1/1991
Appears in Collections:Research Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.